Top

BMC Cardiovascular Disorders

Published in:

01-12-2021 | Coronary Heart Disease | Research article

Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies

Authors: Xiangmei Zhao, Dongying Wang, Lijie Qin

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Abstract

Background

This meta-analysis based on prospective cohort studies aimed to evaluate the associations of lipid profiles with the risk of major adverse cardiovascular outcomes in patients with coronary heart disease (CHD).

Methods

The PubMed, Embase, and Cochrane Library electronic databases were systematically searched for prospective cohort study published through December 2019, and the pooled results were calculated using the random-effects model.

Results

Twenty-one studies with a total of 76,221 patients with CHD met the inclusion criteria. The per standard deviation (SD) increase in triglyceride was associated with a reduced risk of major adverse cardiovascular events (MACE). Furthermore, the per SD increase in high-density lipoprotein cholesterol (HDL-C) was associated with a reduced risk of cardiac death, whereas patients with lower HDL-C were associated with an increased risk of MACE, all-cause mortality, and cardiac death. Finally, the risk of MACE was significantly increased in patients with CHD with high lipoprotein(a) levels.

Conclusions

The results of this study suggested that lipid profile variables could predict major cardiovascular outcomes and all-cause mortality in patients with CHD.

Available only for authorised users

WHO. The top 10 causes of death. Geneva: World Health Organisation; 2019.

Antithrombotic TC. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clin Res Ed). 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.CrossRef

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet (London, England). 2016;387(10022):957–67. https://doi.org/10.1016/S0140-6736(15)01225-8.CrossRef

Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–24. https://doi.org/10.1001/jama.2015.15629.CrossRefPubMed

Karimi F, Rayani M, Akbarzade S, Tahmasebi R, Khakzade M, Arab J. The prevalence of hyperlipidemia in persons over 19 years of Bushehr in 1378. Iran South Med J. 2000;3(2):98–106.

Esmaeili NA, Ahmadi KJ. Lipid abnormalities in urban population of Rafsanjan (Rafsanjan coronary risk factors study phase 1). 2004.

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. https://doi.org/10.1016/j.jacc.2013.11.002.CrossRefPubMed

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272.CrossRefPubMed

Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25(9):846–984. https://doi.org/10.5551/jat.GL2017.CrossRefPubMedPubMedCentral

10.

Moher D, Liberati A, Tetzlaff J, Altman DG, Ge P, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

11.

Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2009.

12.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

13.

Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Mak Int J Soc Med Decis Mak. 2005;25(6):646–54. https://doi.org/10.1177/0272989X05282643.CrossRef

14.

Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Oxford: Wiley; 2008.

15.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRef

16.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:15–7.

17.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed). 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRef

18.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefPubMed

19.

Sigurdsson E, Sigfusson N, Agnarsson U, Sigvaldason H, Thorgeirsson G. Long-term prognosis of different forms of coronary heart disease: the Reykjavik Study. Int J Epidemiol. 1995;24(1):58–68. https://doi.org/10.1093/ije/24.1.58.CrossRefPubMed

20.

Tervahauta M, Pekkanen J, Nissinen A. Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart disease. Finnish cohorts of the Seven Countries Study. JACC. 1995;26(7):1623–9. https://doi.org/10.1016/0735-1097(95)00395-9.CrossRefPubMed

21.

Behar S, Graff E, Reicher-Reiss H, Boyko V, Benderly M, Shotan A, et al. Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group. Eur Heart J. 1997;18(1):52–9. https://doi.org/10.1093/oxfordjournals.eurheartj.a015117.CrossRefPubMed

22.

Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J. 2002;66(12):1096–100. https://doi.org/10.1253/circj.66.1096.CrossRefPubMed

23.

Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2003;138(2):81–9. https://doi.org/10.7326/0003-4819-138-2-200301210-00007.CrossRefPubMed

24.

Leander K, Wiman B, Hallqvist J, Andersson T, Ahlbom A, de Faire U. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). Eur J Cardiovasc Prev Rehabil. 2007;14(4):532–7. https://doi.org/10.1097/HJR.0b013e328012e3cc.CrossRefPubMed

25.

Al-Mallah MH, Hatahet H, Cavalcante JL, Khanal S. Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non ST segment elevation myocardial infarction. Cardiol J. 2009;16(3):227–33.PubMed

26.

Ghazzal ZB, Dhawan SS, Sheikh A, Douglas JS, Veledar E, Mavromatis K, et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol. 2009;103(7):902–6. https://doi.org/10.1016/j.amjcard.2008.11.053.CrossRefPubMed

27.

Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011;97(23):1943–50. https://doi.org/10.1136/hrt.2011.225466.CrossRefPubMed

28.

De Bacquer D, Dallongeville J, Kotseva K, Cooney MT, Pajak A, Deckers JW, et al. Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories. Int J Cardiol. 2013;168(2):910–4. https://doi.org/10.1016/j.ijcard.2012.10.051.CrossRefPubMed

29.

Lin GM, Li YH, Lin CL, Wang JH, Han CL. Low high-density lipoprotein cholesterol and low/normal body mass index are associated with increased mortality in coronary artery disease patients in Taiwan. Circ J. 2013;77(8):2079–87. https://doi.org/10.1253/circj.cj-12-1511.CrossRefPubMed

30.

van de Woestijne AP, Wassink AM, Monajemi H, Liem AH, Nathoe HM, van der Graaf Y, et al. Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol. Int J Cardiol. 2013;167(2):403–8. https://doi.org/10.1016/j.ijcard.2012.01.008.CrossRefPubMed

31.

Ding D, Li X, Qiu J, Li R, Zhang Y, Su D, et al. Serum lipids, apolipoproteins, and mortality among coronary artery disease patients. Biomed Res Int. 2014;2014:709756. https://doi.org/10.1155/2014/709756.CrossRefPubMedPubMedCentral

32.

Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J. 2015;36(1):22–30. https://doi.org/10.1093/eurheartj/ehu264.CrossRefPubMed

33.

Park SH, Rha SW, Choi BG, Park JY, Jeon U, Seo HS, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin Exp Pharmacol Physiol. 2015;42(6):588–95. https://doi.org/10.1111/1440-1681.12396.CrossRefPubMed

34.

Li JJ, Zhang Y, Li S, Cui CJ, Zhu CG, Guo YL, et al. Large HDL subfraction but not HDL-C is closely linked with risk factors, coronary severity and outcomes in a cohort of nontreated patients with stable coronary artery disease: a prospective observational study. Medicine. 2016;95(4):e2600. https://doi.org/10.1097/MD.0000000000002600.CrossRefPubMedPubMedCentral

35.

Liu HH, Guo YL, Wu NQ, Zhu CG, Gao Y, Qing P, et al. High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis. 2017;263:104–11. https://doi.org/10.1016/j.atherosclerosis.2017.06.013.CrossRefPubMed

36.

Tsai IT, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, et al. The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovasc Disord. 2017;17(1):1. https://doi.org/10.1186/s12872-016-0436-7.CrossRefPubMedPubMedCentral

37.

Nordenskjold AM, Baron T, Eggers KM, Jernberg T, Lindahl B. Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. Int J Cardiol. 2018;261:18–23. https://doi.org/10.1016/j.ijcard.2018.03.056.CrossRefPubMed

38.

Dai W, Zhang Z, Zhao S. Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. Lipids Health Dis. 2018;17(1):273. https://doi.org/10.1186/s12944-018-0923-1.CrossRefPubMedPubMedCentral

39.

Winter MP, Wiesbauer F, Blessberger H, Pavo N, Sulzgruber P, Huber K, et al. Lipid profile and long-term outcome in premature myocardial infarction. Eur J Clin Investig. 2018;48(10):e13008. https://doi.org/10.1111/eci.13008.CrossRef

40.

Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909–19. https://doi.org/10.1001/archinternmed.2012.2145.CrossRefPubMed

41.

Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319(15):1566–79. https://doi.org/10.1001/jama.2018.2525.CrossRefPubMedPubMedCentral

42.

de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS ONE. 2014;9(11):e111247. https://doi.org/10.1371/journal.pone.0111247.CrossRefPubMedPubMedCentral

43.

Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93(8):914–21. https://doi.org/10.1136/hrt.2006.112508.CrossRefPubMedPubMedCentral

44.

Yan YL, Qiu B, Hu LJ, Jing XD, Liu YJ, Deng SB, et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2013;69(12):2001–9. https://doi.org/10.1007/s00228-013-1570-0.CrossRefPubMed

45.

Morishita R, Itakura H, Nakaya N, Yoshida M, Odawara M, Ichihara A, et al. Risk factors for cardiovascular events in Japanese patients treated with fluvastatin from the long-term event monitoring (LEM) study. Curr Vasc Pharmacol. 2012;10(2):178–86. https://doi.org/10.2174/157016112799305049.CrossRefPubMed

46.

Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016;9(2):100–8. https://doi.org/10.1161/CIRCOUTCOMES.115.002104.CrossRefPubMed

47.

Besler C, Luscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4(4):251–68. https://doi.org/10.1002/emmm.201200224.CrossRefPubMedPubMedCentral

48.

Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352–64. https://doi.org/10.1161/01.RES.0000225982.01988.93.CrossRefPubMed

49.

Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845–52. https://doi.org/10.1001/jama.283.14.1845.CrossRefPubMed

Title: Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies
Authors: Xiangmei Zhao
Dongying Wang
Lijie Qin
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Coronary Heart Disease
Published in: BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-020-01835-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prognostic implications of left ventricular mass-geometry in patients with no or nonobstructive coronary artery disease

High-fat diet attenuates the improvement of hypoxia-induced pulmonary hypertension in mice during reoxygenation

Exploration and validation of hub genes and pathways in the progression of hypoplastic left heart syndrome via weighted gene co-expression network analysis

Risk of major bleeding by ethnicity and socioeconomic deprivation among 488,107 people in primary care: a cohort study

Immunotherapy reversed myopathy but not cardiomyopathy in a necrotizing autoimmune myopathy patient with positive anti-SRP and MDA-5 autoantibodies

The effect of preventative cardiovascular therapies on coronary artery disease in people with and without type 2 diabetes: a propensity-matched score study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page